Novavax, Inc. (NASDAQ:NVAX) registered a -3.76% decrease, still its new closing price is 10.34% up from the company’s 1 year high of 8.49.It posted -5.19% losses in previous 5 sessions and is now the subject of 7 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 9 stock analysts following this company have an average price target at $3.29, with individual PT in the $1.50-$12.00 range. The shares moved at $1.28, implying that brokerage firms see shares losing about -75.15% in twelve months time.
Novavax, Inc. (NVAX) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 1.59% rise year to date. A President, R&D at Novavax, Inc. (NVAX) acquired shares in a transaction closed on Wednesday December 07, 2016. Glenn Gregory M bought 1,000 shares in the company at $1.45 each and collected $1,000 in proceeds. Glenn Gregory M now owns 4,427 shares in the company after this transaction. A SVP, Commercial Operations in the company, Trizzino John, disclosed a transaction on Thursday September 22, 2016 that ended up paying $99,001 from the purchase of 46,000 shares at $2.17 per share.
Novavax, Inc. (NASDAQ:NVAX) Upcoming Results on Tap
Novavax, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.16 in that period. Sales during the quarter are predicted to arrive at $6.21 million.
Earnings surprise history: Last quarter, the company posted approximately $3.23 million in revenue and EPS of $-0.24. The mean forecast was for $3.9 million and $-0.26 a share, respectively. One quarter earlier, revenue for the stock was at $2.51 million, with earnings at $-0.29/share.
Novavax, Inc. (NVAX) Brokerage Update
Novavax, Inc. (NVAX) is in Citigroup’s research list so their analyst rating change is noteworthy. These shares were downgraded to Neutral from Buy by Citigroup, according to news reported on Friday September 16, 2016.Another important research note was issued by Wedbush on Friday September 16, 2016.The firm downgraded NVAX to Neutral from Outperform. Over the last six months and over the last three months, the shares of Novavax, Inc. (NVAX), have changed -82.51% and -15.23%, respectively.